CRNX stock icon

Crinetics Pharmaceuticals
CRNX

$44.21
0.18%
 

About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Employees: 210

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 27 analysts
0
News positive %
of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

61% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 28

50% more capital invested

Capital invested by funds: $2.51B [Q4 2023] → $3.76B (+$1.25B) [Q1 2024]

44% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2023] → 13 (+4) [Q1 2024]

42% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 55

21% more call options, than puts

Call options by funds: $34.1M | Put options by funds: $28.1M

9% more funds holding

Funds holding: 181 [Q4 2023] → 198 (+17) [Q1 2024]

2.59% less ownership

Funds ownership: 105.77% [Q4 2023] → 103.18% (-2.59%) [Q1 2024]

Research analyst outlook

27 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$48
9%
upside
Avg. target
$63
42%
upside
High target
$97
119%
upside

27 analyst ratings

27 positive
100%
neutral
0%
negative
0%
JMP Securities
Jonathan Wolleben
81%upside
$80
Market Outperform
Reiterated
4 Jun 2024
Oppenheimer
Leland Gershell
67%upside
$74
Outperform
Maintained
4 Jun 2024
HC Wainwright & Co.
Douglas Tsao
36%upside
$60
Buy
Reiterated
4 Jun 2024
Baird
Brian Skorney
40%upside
$62
Outperform
Maintained
23 May 2024
Morgan Stanley
Jeffrey Hung
58%upside
$70
Overweight
Maintained
23 May 2024

Financial journalist opinion

Based on 8 articles about CRNX published over the past 30 days